SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Nurtec

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available in the U.S. (since 2020) and multiple international markets.
Why 4/10
Nurtec is already FDA-approved and commercially marketed with no pending PDUFA date, pivotal readout, or other hard binary catalyst scheduled in the next ~12 months. The pediatric Phase 3 trials are still recruiting with expected completion years away. As an approved product at a large diversified pharma, the impact score defaults to 4.
Actionable Insight NEUTRAL

Nurtec is an approved, commercially established drug with no near-term binary catalyst. Watch quarterly revenue growth trajectory (Q3 2026: $547M, +33% YoY) as a gauge of commercial momentum, and monitor the pediatric Phase 3 programs for potential label expansion, though those are years from completion. Generic entry risk is distant (~2039).

Price Chart

Loading chart...

Executive Summary

Nurtec ODT (rimegepant) is an FDA-approved oral CGRP receptor antagonist (gepant) for both acute treatment and prevention of migraine in adults, the only drug with both indications. Originally developed by Biohaven Pharmaceutical, it was acquired by Pfizer in October 2022 for approximately $11.6 billion. Nurtec generated $547 million in Q3 2026 revenue (up 33% operationally year-over-year), driven by strong U.S. demand and international expansion. The drug faces competition from other oral gepants (AbbVie's Qulipta and Ubrelvy) and injectable anti-CGRP antibodies, but its dual indication and oral formulation are competitive advantages. Patent protection extends to approximately 2039, with no generic available yet. Pediatric Phase 3 trials are ongoing but years from completion. For Pfizer, a $63B+ revenue diversified pharma, Nurtec is a meaningful growth asset but not a binary driver of the stock.

How It Works

Nurtec ODT (rimegepant) belongs to a class of drugs called gepants. It works by blocking the CGRP (calcitonin gene-related peptide) receptor. CGRP is a protein that rises during a migraine attack and contributes to pain signaling and inflammation in the brain. By blocking CGRP from binding to its receptor, Nurtec can both treat an active migraine and, when taken every other day, help prevent future migraines. It dissolves on or under the tongue without needing water.

Trial Status

Nurtec ODT is FDA-approved for both acute treatment (Feb 2020) and preventive treatment (May 2021) of migraine in adults. Pfizer is conducting Phase 3 pediatric trials for migraine prevention (NCT05156398, still recruiting, estimated completion 2032) and acute treatment (NCT04649242) in children aged 6-17. A Phase 3 study in China (NCT05810038) was completed in December 2025 with 787 enrolled subjects. Several supplemental NDAs for labeling updates were approved in 2025-2026.

The Two-Sided Case

▲ Bull Case5
Nurtec is the first and only migraine medication approved for both acute treatment and prevention in adults, a key differentiating feature versus most competitors.
Q3 2026 revenue of $547M grew 33% operationally year-over-year, driven by strong U.S. demand and international launch uptake, showing robust commercial momentum.
The global migraine market is large and growing, with the Nurtec ODT market estimated at $2.41B in 2025 and projected to reach $7.21B by 2034.
Patent protection until ~2039 provides a long runway of exclusivity, and pediatric label expansion (Phase 3 trials ongoing) could open a new patient population.
Pfizer raised full-year 2026 guidance after Q3 results, with launched and acquired products (including Nurtec) growing 32% operationally.
▼ Bear Case4
Nurtec faces intensifying competition from other oral CGRP antagonists including AbbVie's Qulipta (atogepant) and Ubrelvy (ubrogepant), plus Pfizer's own Zavzpret (zavegepant), which could pressure market share and pricing.
As a small part of Pfizer's $63B+ annual revenue, Nurtec's performance has limited ability to move PFE shares meaningfully on its own.
Tentative FDA approvals for generic rimegepant (ANDA 219399, ANDA 219440) have been granted, signaling eventual generic entry, though patents are expected to protect the brand until ~2039.
Pfizer's post-COVID revenue decline and patent cliffs on other major products (e.g., Eliquis, Xeljanz, Ibrance) create broader headwinds that overshadow Nurtec's growth.

Upcoming Catalysts

  • Quarterly revenue reports tracking Nurtec ODT/Vydura commercial growth trajectory (next: Q4 2026, early 2027)
  • Pediatric Phase 3 trial readouts (NCT05156398, NCT04649242) - years away, estimated completion 2032
  • Potential international market launches and reimbursement expansions

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 16

Hover a chip for the title
1 pfizer.com2 pfizer.com3 fool.com4 fiercepharma.com5 biospace.com6 drugs.com7 drugs.com8 growthmarketreports.com9 drugpatentwatch.com10 accessdata.fda.gov11 accessdata.fda.gov12 clinicaltrials.gov13 biospace.com14 biospace.com15 qz.com16 cnbc.com